Abstract. Serum progranulin is decreased in frontotemporal dementia (FTD) patients with progranulin gene (PGRN) mutations. We investigate the utility of prospective serum screening as a surrogate diagnostic marker for progranulin mutations. A commercial ELISA was used to measure progranulin protein concentration in serum from 63 FTD patients and 32 normal controls, and DNA screening then performed. Four patients (2/17 behavioral variant, 2/8 corticobasal syndrome) had abnormally low progranulin levels with PGRN mutations confirmed on DNA testing. Surprisingly, elevated levels were found in 6/16 patients with progressive non-fluent aphasia, the significance of which is unclear. Serum testing is an accurate and cost effective means of predicting PGRN mutations.
INTRODUCTION
Progranulin (PGRN) gene mutations have been found in approximately 8% of frontotemporal dementia (FTD) patients [1] and are associated with reduced brain and serum levels of progranulin [2] . Mutations are most common in patients with behavioral variant FTD (bvFTD), and least common in semantic dementia (SD) and FTD with motor neuron disease (FTD-MND) [1] . PGRN null-mutations are associated with an approximate four-fold reduction in blood plasma progranulin levels relative to controls [2] . A smaller reduction in serum progranulin is also related to missense mutations [3] whilst benign polymorphisms caused no change in serum levels. Studies to date have * Correspondence to: Professor Glenda Halliday, Neuroscience Research Australia, Barker Street, Randwick, NSW 2031, Australia. Tel.: +61 2 9399 1174; Fax: +61 2 9399 1105; E-mail: g.halliday@ neura.edu.au. compared patient groups with mutations to those without [4] , rather than to normal controls. Genetic screening is expensive and of limited availability, especially in the developing world. We investigated the diagnostic utility of serum progranulin levels as a surrogate marker for PGRN mutations in a prospective study of FTD patients of all subtypes.
METHODS
Serum and DNA samples were collected from consecutive patients with FTD attending a specialist FTD clinic (FRONTIER) in Sydney, Australia. Written informed consent was obtained for all participants in this study and the study was approved by the Human Research Ethics Committees of the South Eastern Sydney and Illawarra Health Service-Northern Hospital Network, and the University of New South Wales. All patients underwent a full neurological and cognitive assessment by an experienced neurologist (JRH). Care- givers were interviewed to establish behavior changes and any family history of a related neurodegenerative disorder. All underwent a 3T MRI. Diagnosis was by consensus and based upon current criteria [5] . Postmortem confirmation of diagnosis is not available at this time. A total of 63 patients were included comprising: bvFTD (n = 17), SD (n = 11), progressive non-fluent aphasia (PNFA, n = 16), FTD-MND (n = 11), or corticobasal syndrome (CBS, n = 8). Whole blood was collected into a 9 ml lithium heparin tube (Greiner bio-one, Kremsmünster, Austria) and underwent DNA extraction according to standard protocols. Blood was also collected into a 10 ml serum separator tube (Bectin and Dickinson, Texas, USA), left at room temperature for 30 min to clot, then centrifuged at 1300 g for 10 min at 4
• C. The serum layer was removed, aliquotted into 300 µL lots and stored frozen at −80
• C. Control serum samples from 32 age-and sex-matched individuals with no neurological disorder was selected from a serum bank at POWMRI stored at −80
• C. Enzyme-linked immunosorbent assay kits designed to detect progranulin (Adipogen, Korea) were used to assess the level of progranulin protein in each sample against a standard recombinant protein expressed in HEK 293 cells. Absorbance readings were corrected for a blank well and protein concentration extracted from a standard curve. DNA from 24/63 (38%) subjects who had 1) positive family histories, 2) lower than control average serum progranulin levels, or 3) high serum progranulin levels and a FTD diagnosis were screened for PGRN and microtubule associated protein tau (MAPT) gene mutations. Intronic polymerase chain reaction (PCR) primers were designed to amplify each non-coding and coding exon, as well as flanking intronic sequence of GRN using the ExonPrimer program accessed using the UCSC Genome Bioinformatics Site (primer sequences available on request). PCR products amplified from genomic templates were sequenced using Big Dye Chemistry (Applied Biosystems). In those subjects examined, family history was re-examined in detail to investigate any previously unknown first or Fig. 1 . Serum progranulin in FTD compared to controls. Box plot of serum progranulin levels (ng/ml) for controls (n = 32) and patients with FTD (n = 63, including all subtypes). Boxes indicate median and interquartile range. Groups are significantly different from one another (Mann-Whitney U, p = 0.017). Dots (λ) represent outliers 1.5 times the interquartile range and above. Labels 1-4 indicate abnormally low serum progranulin levels. Details of these four patients are summarized in Table 2. second degree relatives with another neurodegenerative condition.
RESULTS
The range of control values (Table 1) was very similar to that reported [2, 3] . When all FTD subtypes were considered together in comparison to controls, there was a significant reduction in the mean levels of serum progranulin of 15 ng/ml (Mann Whitney U, p = 0.017, Fig. 1 ). Serum progranulin levels were abnormally low (< 2.5 standard deviations from mean control level) in 6%. In addition, seven subjects were found to have Yes [7] a Number of standard deviations below mean control serum progranulin. b Mutation annotated relative to nucleotide position number 1 in Genebank genomic sequence NG 007886.1. c Segregation of mutation observed within pedigree.
abnormally high levels of serum progranulin, the majority with PNFA (6 subjects) and one with FTD-MND (Table 1) . Screening for PGRN mutations was undertaken in the four FTD subjects with abnormally low serum progranulin levels (Fig. 1) . All four had young onset FTD (ages 53 to 58) and were ethnicity diverse; two had bvFTD and two CBS. All four patients were found to have nucleotide substitutions, or insertions/deletions in the coding sequence of the PGRN gene that are predicted to result in truncated proteins ( Table 2) . Three of these nucleotide changes were known pathogenic mutations, whilst patient 2 had a novel nucleotide deletion (g.10577delT) in exon 7 that is predicted to give rise to a frame-shift at condon 203 (p.Ser203fx) in the PGRN transcript. Of interest, identical frameshift mutations in the PGRN transcript (p.Ser203fx), arising from different nucleotide deletions, have been reported in other FTLD pedigrees [7] . Only two reported an autosomal dominant pattern of inheritance, the other had a weaker family history which was only later uncovered by further genealogical analysis. We were able to demonstrate segregation of the g.9132 9133insCTGC in a daughter and her father, and the g.11303C > T PGRN mutation in two affected cousins.
DISCUSSION
This is the first study to prospectively confirm that serum progranulin protein levels can identify FTD patients with null mutations in the PGRN gene. In the four patients with at least a 2.5 standard deviation depression of serum prograunlin, there was 100% accuracy in determining PGRN abnormalities. The identification of mutations in bvFTD and CBS subtypes, and not in language subtypes of FTD, is in line with the reported incidence of PGRN mutations [1, 6] . An interesting additional finding was that abnormally high levels of progranulin protein were detected in patients with PN-FA (38% of subjects), whilst patients with SD, all had serum progranulin levels within the normal range.
In one retrospective study, 94 ng/ml was measured for null mutations although those with pathogenic missense mutations had higher levels that overlapped with healthy controls [4] . Another study of progranulin protein in plasma identified 74.4 ng/ml as a cutoff [2] , a level more in line with our findings. We propose that a serum progranulin level of 67 ng/ml might be an optimal cutoff below which a PGRN mutation would be highly likely. We also note that there was no correlation between the level of serum progranulin protein and position of the PGRN mutation, as mutations in exon 9 resulted in the lowest and highest serum progranulin levels within the group of four PGRN mutation carriers.
There is no clear hypothesis for the increased levels of progranulin in PNFA which is typically associated with tau pathology [8] , although it suggests that levels of progranulin protein may be modulated by other pathological variations.
In conclusion, given the expense of genetic screening and the difficulties sometimes in establishing a relevant family history, the clinical utility of serum progranulin screening in FTD patients is considerable.
